324 related articles for article (PubMed ID: 2334921)
1. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
[TBL] [Abstract][Full Text] [Related]
2. Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937).
Erlichman C; Moore M; Kerr IG; Wong B; Eisenhauer E; Zee B; Whitfield LR
Cancer Res; 1991 Dec; 51(23 Pt 1):6317-22. PubMed ID: 1933893
[TBL] [Abstract][Full Text] [Related]
3. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
Diab SG; Baker SD; Joshi A; Burris HA; Cobb PW; Villalona-Calero MA; Eckhardt SG; Weiss GR; Rodriguez GI; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Feb; 5(2):299-308. PubMed ID: 10037178
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.
Graham MA; Newell DR; Foster BJ; Gumbrell LA; Jenns KE; Calvert AH
Cancer Res; 1992 Feb; 52(3):603-9. PubMed ID: 1732048
[TBL] [Abstract][Full Text] [Related]
5. Phase I and clinical pharmacological evaluation of pirozantrone hydrochloride (oxantrazole).
Ames MM; Loprinzi CL; Collins JM; van Haelst-Pisani C; Richardson RL; Rubin J; Moertel CG
Cancer Res; 1990 Jul; 50(13):3905-9. PubMed ID: 2191768
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor.
Berg SL; Savarese DM; Balis FM; Denicoff AM; Hillig M; O'Shaughnessy JA; Poplack DG; Cowan KH
Cancer Res; 1993 Jun; 53(11):2587-90. PubMed ID: 7684320
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
Pitot HC; McElroy EA; Reid JM; Windebank AJ; Sloan JA; Erlichman C; Bagniewski PG; Walker DL; Rubin J; Goldberg RM; Adjei AA; Ames MM
Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703
[TBL] [Abstract][Full Text] [Related]
10. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
11. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Vogelzang NJ; Mick R; Janisch L; Berezin F; Schilsky RL; Ratain MJ
Cancer Res; 1994 Jan; 54(1):114-9. PubMed ID: 8261430
[TBL] [Abstract][Full Text] [Related]
13. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
Hendricks CB; Grochow LB; Rowinsky EK; Forastiere AA; McGuire WP; Ettinger DS; Sartorius S; Lubejko B; Donehower RC
Cancer Res; 1991 Nov; 51(21):5781-5. PubMed ID: 1933848
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacological study of merbarone.
Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904.
Albain KS; Liu PY; Hantel A; Poplin EA; O'Toole RV; Wade JL; Maddox AM; Alberts DS
Gynecol Oncol; 1995 Jun; 57(3):407-11. PubMed ID: 7774846
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
Noe DA; Rowinsky EK; Shen HS; Clarke BV; Grochow LB; McGuire WB; Hantel A; Adams DB; Abeloff MD; Ettinger DS
Cancer Res; 1990 Aug; 50(15):4595-9. PubMed ID: 2369734
[TBL] [Abstract][Full Text] [Related]
20. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
